直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
  • Articles & Books
    • Ad Law Buzz Blog
    • At the PTAB Blog
    • European IP Blog
    • Federal Circuit IP Blog
    • INCONTESTABLE® Blog
    • Prosecution First Blog
  • Events & Webinars
  • IP Updates
  • Podcasts
    • AI + Finnegan
    • AI + Copyright
    • AI + Patent
    • AI + Privacy
    • AI + Trade Secrets
    • AI + Trademark
  • Unified Patent Court (UPC) Hub

Book

Preclinical Patent Considerations

2014

Pre-ANDA Litigation: Strategies and Tactics for Developing a Drug Product and Patent Portfolio, First Edition

By Mark J. Feldstein, Ph.D.; Shana K. Cyr, Ph.D.

All pharmaceutical companies, whether they are an innovator or a generic, must navigate the same complex legal and regulatory framework to bring a product to market and fend off competition. Pre-ANDA Litigation: Strategies and Tactics for Developing a Drug Product and Patent Portfolio, is an in-depth resource for learning about and planning for ANDA litigations and all the different avenues that pharmaceutical litigants could follow. 

From the perspective of an innovator company, patents are vital to protect new drug products both to recoup the initial investment and for future investments. For the innovator and patent owner, the patentee must be aware of the risk to those intellectual property rights and be prepared for any patent challenge. Both entities can use Pre-ANDA Litigation as a resource to help formulate a strategy before patent litigation begins. 

ANDA Patent litigations and strategies are complex and require the patent professional to be able to explain complex technical and legal issues to lay persons, both within the organization and to judges and juries. This compendium provides lawyers with invaluable and in-depth tactics and advice so that any pharmaceutical litigant wanting to increase market share, whether as an innovator or a generic, can plan early and be ready to alter plans as new events occur. Finnegan attorneys authored the following chapters:

  • Coordinating New Drug application (NDA) and Patent Portfolio Strategy
  • Preclinical Patent Considerations
  • Trademark (TM) and nonproprietary name considerations
  • Acquiring and In-Licensing Pharmaceutical Products: Due Diligence Issues

Related Industries

Life Sciences

Pharmaceutical

Related Professionals

Mark J. Feldstein, Ph.D.
Partner
Washington, DC
+1 202 408 4092
Email

Related Insights

Conference

IAM Live: Navigating the UPC 2026

November 3, 2026

Paris

Conference

4th Global Patent Litigation FORUM

October 29, 2026

Munich

Conference

2026 EDTX Bench Bar Conference

October 28-30, 2026

Fort Worth

Hybrid Conference

Intellectual Property Law Institute 2026 – California

October 19-20, 2026

San Francisco

Hybrid Conference

Intellectual Property Law Institute 2026 – New York

September 28-29, 2026

New York

Conference

2026 IPO Annual Meeting

September 27-29, 2026

Toronto

Conference

IAM Live: SEP Summit Global 2026

September 9-10, 2026

London

Lecture

Resolving Patent Suits Without Settlement Payments

September 3, 2026

Virtual

Conference

Georgia Life Sciences Summit 2026

August 25-26, 2026

Sandy Springs

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP